-
The first in the world! The recombinant new crown vaccine developed by the Chinese Academy of Sciences is approved for emergency use
Time of Update: 2021-04-13
According to the Institute of Microbiology, Chinese Academy of Sciences, the production of recombinant new coronavirus vaccines uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.
-
More than 130 million cases of new crown confirmed worldwide can resume travel in the U.S. after vaccination
Time of Update: 2021-04-13
Asia: The Philippines is increasing the number of diagnoses and hitting a new highThe Philippine Ministry of Health released the epidemic data on the 2nd, showing that the Philippines has 15,310 new confirmed cases, a record high in a single day, with a total of 771,497 cases.
-
Zhejiang will complete the first dose of 23.4 million people before the end of April!
Time of Update: 2021-04-13
Formulate and issue a special action plan to clearly require strengthening the quality supervision of the new coronavirus vaccine, carrying out daily inspections and inspections, and strictly investigating and punishing violations of vaccine storage and transportation management regulations, illegal supply of vaccines, and illegal production and sale of fake and inferior vaccines.
-
Air ticket, board and lodging all inclusive!
Time of Update: 2021-04-13
This time the Guizhou medical aid delegation is only the first team to return to Ezhou.
It is a famous "city of hundreds of lakes" and "land of fish and rice.
-
New crown vaccine inoculation exceeds 100 million, Sinopharm designs vaccine to strengthen injection to improve antibody persistence
Time of Update: 2021-04-13
At a press conference held by the Joint Prevention and Control Mechanism of the State Council, Zhang Yuntao, vice president of Sinopharm China Biotechnology, said that from the preliminary results obtained, the booster injection of the new crown vaccine can effectively improve the durability of antibodies and improve the ability of the vaccine to resist mutation.
-
FP-025 for the treatment of COVID-19-related ARDS, Phase II/III clinical trials have officially started
Time of Update: 2021-04-13
Infected blood vesselsThe pharmaceutical company Foresee announced today that its highly selective oral MMP-12 inhibitor FP-025 will be used to treat severe COVID-19 patients with acute respiratory distress syndrome (ARDS) in a Phase II/III clinical trial in adult patients.
-
Blood donation can be done 48 hours after the new crown vaccination, but it is recommended to postpone blood donation in 4 situations
Time of Update: 2021-04-13
The Guidelines stated that in accordance with the principle of steady advancement, after full discussion by relevant experts, refer to the current "Requirements for Health Examination of Blood Donors".
-
WuXi Biologics will take over the German pharmaceutical factory for the production of new crown vaccines, etc.
Time of Update: 2021-04-13
In December of last year, WuXi Biologics announced that it would acquire Bayer Group's biological drug solution manufacturing plant in Wupperta at a price of 150 million euros to continue to expand its global production capacity.
-
Greece launches new crown self-inspection tool to recruit private doctors to fight the epidemic
Time of Update: 2021-04-13
Since all the previously equipped intensive care beds for the new crown in Athens and surrounding areas have been put into use, the Greek government has announced that it will further cooperate with the private health department to prevent the national medical system from collapsing under heavy pressure.
-
Ministry of Foreign Affairs: China is providing vaccine assistance to 80 countries and 3 international organizations
Time of Update: 2021-04-13
According to reports, WHO Director-General Tan Desai said on the 29th that the gap between the number of new crown vaccines controlled by rich countries and the number of vaccines obtained by poor countries through the COVAX mechanism is widening every day.
-
ZYESAMI treats COVID-19 respiratory failure, phase IIb/III clinical trial achieves positive results
Time of Update: 2021-04-13
COVID-19-related respiratory failure is caused by selective infection of ATII cells with SARS-CoV-2 virus .
Coronavirus infection of ATII cells shuts down the production of surfactants, triggers the formation of inflammatory cytokines, and leads to cell death.
-
The Lancet: The future scenario of the "new crown pneumonia" epidemic: cooperation will benefit, fight will hurt
Time of Update: 2021-04-13
" Vaccines by themselves cannot end the pandemic or return the world to "business as usual" unless they achieve high population coverage, provide long-term protection, and effectively prevent the spread of SARS-CoV-2 and new coronary pneumonia.
-
China calls for the promotion of equitable vaccine distribution in the UN Human Rights Council
Time of Update: 2021-04-13
On March 23, the 46th session of the United Nations Human Rights Council passed the resolution jointly proposed by Azerbaijan, Ecuador and others to "ensure fair and timely access to affordable vaccines for all countries in response to the new crown pneumonia epidemic.
-
"The trouble of choice"!
Time of Update: 2021-04-13
Because when this type of vaccine is vaccinated again, the human body mainly produces a memory response to the "car"-the adenovirus vector, rather than the "cargo"-the "new coronavirus antigen gene".
-
American journal of obstetrics and gynecology: The response of pregnant and lactating women to the new coronary pneumonia vaccine
Time of Update: 2021-04-13
They evaluated the immunogenicity and reactivity of the new coronary pneumonia gene vaccine in pregnant and lactating women, and compared it with (1) non-pregnant controls and (2) natural infection of new crowns during pregnancy.
-
The effectiveness of AstraZeneca vaccine is reduced by 3%, India now has double mutant virus | New Crown Weekly Research Progress
Time of Update: 2021-04-13
Bispecific antibodies can treat new coronavirus variantsBispecific antibodies can treat new coronavirus variants Bispecific antibodies can treat new coronavirus variantsSource: NatureSource: Nature Source: NatureOn March 25, a paper published in Nature showed that researchers found an antibody that can strongly neutralize SARS-CoV-2 and its variants, and protect mice from COVID-19 .
-
AstraZeneca's new crown vaccine has a protective effect of 79%, and no serious thrombotic events have been found
Time of Update: 2021-04-13
At the same time as the interim analysis results of the phase III clinical trial were announced, AstraZeneca also stated that the independent data safety monitoring committee did not find safety problems related to the vaccine, and no serious thrombotic events were found in the vaccinated subjects.
-
Lancet: The dulutvir-emtricitabine-tenofovir alafenamide treatment program is currently the safest and most effective HIV treatment program for pregnant women
Time of Update: 2021-04-13
For HIV-positive pregnant women, antiretroviral treatment regimens containing dulutvir have advantages in suppressing the virus, preventing mother-to-child transmission during delivery, reducing adverse pregnancy outcomes and the incidence of maternal and infant adverse events.
-
The number of people vaccinated against the new crown in Beijing exceeded 10 million, and 551 elderly people over 90 were vaccinated
Time of Update: 2021-04-13
Pang Xinghuo, deputy director of the Beijing Centers for Disease Control and Prevention, said that there are phase I/II clinical data showing that the safety of vaccination for people over 60 years old is good, and the vaccine will have a certain protective effect, so vaccination is recommended.
-
Lancet: Should breastfeeding women get the new crown vaccine?
Time of Update: 2021-04-13
" The new crown pneumonia vaccine should be provided to lactating individuals similar to non-lactating individuals, as long as they meet the vaccination criteria"In order to improve the health of mothers and babies and maintain public confidence in vaccines, vaccine manufacturers and regulatory agencies must work closely with lactation scientists, infectious disease experts, and public health experts to evaluate the safety of vaccines for breastfeeding women in the early stages of product development.